Arvinas, Inc.
ARVN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001655759
In the last 90 days, Arvinas, Inc. insiders filed 0 open-market purchases and 1 sale; 201 institutions reported holding it in 13F filings for Q2 2026, worth $468.7M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $452.5M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.48K in total
- 1
- 13F holdersQ2 2026, −4 vs. previous quarter
- 201
- 13F valueReported value at the end of Q2 2026
- $468.7M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $262.6M
- −0.3% year over year
- Net income, FY2025
- -$80.8M
- No comparable prior period
- Free cash flow, FY2025
- -$275.7M
- No comparable prior period
- Revenue, Q3 FY2026
- $500.0K
- −98.8% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $80.8M (30.8% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 5.75M
- Shares sold short
- Change
- +159.0K
- +2.8% vs. previous
- Days to cover
- 7.59
- At average daily volume
Superinvestors holding ARVN, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ARVN at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Arvinas, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 9, 2026 (view filing)6:04 PM ET | Nov 9 | Same day | Loomis David KVP, Chief Accounting Officer | SSale | −232 | $6.36 | −$1.48K | −0.6%40.0K after | 10b5-1 |
| Jun 24, 2026 (view filing) | Jun 24 | Same day | Saik AndrewChief Financial Officer | SSale | −5.70K | $8.16 | −$46.5K | −2.9%187.4K after | 10b5-1 |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Cacace Angela MChief Scientific Officer | SSale | −2.58K | $7.60 | −$19.6K | −1.4%180.4K after | 10b5-1 |
| May 22, 2026 (view filing) | May 21 | 1 day | Teel RandyPresident and CEO | SSale | −2.21K | $9.04 | −$20.0K | −0.8%285.0K after | |
| May 13, 2026 (view filing) | May 11 | 2 days | Saik AndrewChief Financial Officer | SSale | −11.1K | $9.94 | −$110.7K | −5.5%193.1K after | |
| May 13, 2026 (view filing) | May 11 | 2 days | Loomis David KVP, Chief Accounting Officer | SSale | −1.92K | $9.94 | −$19.1K | −4.6%40.2K after | |
| May 13, 2026 (view filing) | May 11 | 2 days | Cacace Angela MChief Scientific Officer | SSale | −9.66K | $9.94 | −$96.0K | −5.0%183.0K after | |
| May 13, 2026 (view filing) | May 11 | 2 days | Berkowitz NoahChief Medical Officer | SSale | −11.1K | $9.94 | −$110.4K | −5.5%191.4K after | |
| May 13, 2026 (view filing) | May 11 | 2 days | Teel RandyPresident and CEO | SSale | −9.66K | $9.94 | −$96.0K | −3.3%287.2K after | |
| Mar 19, 2026 (view filing) | Mar 18 | 1 day | Berkowitz NoahChief Medical Officer | SSale | −6.43K | $11.10 | −$71.4K | −3.1%202.5K after |
Top 10 13F holders, Q2 2026
See all 201 holdersThe largest institutional positions in Arvinas, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,609,123 | $63.2M | 0.00% | +811,539+11.9% | Added |
| Vanguard Portfolio Management LLC | 4,123,399 | $34.3M | 0.00% | +233,771+6.0% | Added |
| D. E. Shaw & Co., Inc. | 3,495,153 | $29.0M | 0.02% | −143,414−3.9% | Reduced |
| Pfizer Inc | 3,457,815 | $27.7M | 16.24% | 00.0% | Unchanged |
| Armistice Capital, LLC | 2,796,000 | $23.2M | 0.64% | +818,000+41.4% | Added |
| Vanguard Capital Management LLC | 2,714,163 | $22.6M | 0.00% | +24,801+0.9% | Added |
| Two Sigma Investments, LP | 2,573,447 | $21.4M | 0.02% | +741,333+40.5% | Added |
| State Street Corp | 2,196,872 | $18.3M | 0.00% | +368,400+20.1% | Added |
| Nextech Invest, Ltd. | 1,122,713 | $17.1M | 0.81% | +583,319+108.1% | Added |
| Geode Capital Management, LLC | 1,667,265 | $13.9M | 0.00% | +110,158+7.1% | Added |
Holders of 5% or more of ARVN
See all 3 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Arvinas, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 7.90%5.42M shares | – | Oct 22, 20243 filings | Apr 17, 2025 | SEC |
| Vanguard Portfolio Management LLC | 13G | 6.12%3.92M shares | New | Apr 28, 20261 filing | Apr 28, 2026 | SEC |
| D. E. Shaw & Co, L.P. | 13G/A | 5.40%3.50M shares | +0.10 ppfrom 5.30% | Nov 14, 20252 filings | Aug 14, 2026 | SEC |